Literature DB >> 31648690

Psoriasis: Past, Present, and Future.

Allison C Billi1, Johann E Gudjonsson2, John J Voorhees1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31648690      PMCID： PMC6989032          DOI： 10.1016/j.jid.2019.08.437

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  124 in total

1.  Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

Authors:  K Reich; P Rich; C Maari; R Bissonnette; C Leonardi; A Menter; A Igarashi; P Klekotka; D Patel; J Li; J Tuttle; M Morgan-Cox; E Edson-Heredia; S Friedrich; K Papp
Journal:  Br J Dermatol       Date:  2019-04-17       Impact factor: 9.302

2.  Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials.

Authors:  M A Stawiski; L J Rusin; T L Burns; G D Weinstein; J J Voorhees
Journal:  J Invest Dermatol       Date:  1979-10       Impact factor: 8.551

3.  Chemotactic leukotrienes in psoriasis.

Authors:  J Grabbe; B M Czarnetzki; M Mardin
Journal:  Lancet       Date:  1982-12-25       Impact factor: 79.321

4.  Resolved psoriasis lesions retain expression of a subset of disease-related genes.

Authors:  Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Michelle A Lowes; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-09-23       Impact factor: 8.551

5.  Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom.

Authors:  Junko Takeshita; Daniel B Shin; Alexis Ogdie; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2018-03-02       Impact factor: 8.551

6.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

7.  Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.

Authors:  Dorothea M Sommer; Stefan Jenisch; Michael Suchan; Enno Christophers; Michael Weichenthal
Journal:  Arch Dermatol Res       Date:  2006-09-22       Impact factor: 3.017

8.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.

Authors:  S L Gottlieb; P Gilleaudeau; R Johnson; L Estes; T G Woodworth; A B Gottlieb; J G Krueger
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

9.  The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis.

Authors:  S Brain; R Camp; P Dowd; A K Black; M Greaves
Journal:  J Invest Dermatol       Date:  1984-07       Impact factor: 8.551

10.  Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a.

Authors:  Ka Lun Cheung; Rachael Jarrett; Sumithra Subramaniam; Maryam Salimi; Danuta Gutowska-Owsiak; Yi-Ling Chen; Clare Hardman; Luzheng Xue; Vincenzo Cerundolo; Graham Ogg
Journal:  J Exp Med       Date:  2016-09-26       Impact factor: 14.307
View more
  10 in total

1.  The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis.

Authors:  Lanmei Lin; Yilun Wang; Xiaonian Lu; Tianxiao Wang; Qunyi Li; Runnan Wang; Jinfeng Wu; Jinhua Xu; Juan Du
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 2.  The Relapse of Psoriasis: Mechanisms and Mysteries.

Authors:  Danning Tian; Yuping Lai
Journal:  JID Innov       Date:  2022-03-09

3.  A Tissue-Engineered Human Psoriatic Skin Model to Investigate the Implication of cAMP in Psoriasis: Differential Impacts of Cholera Toxin and Isoproterenol on cAMP Levels of the Epidermis.

Authors:  Mélissa Simard; Sophie Morin; Geneviève Rioux; Rachelle Séguin; Estelle Loing; Roxane Pouliot
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

4.  Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.

Authors:  Han Cao; Shengmin Su; Qi Yang; Yunchen Le; Lihong Chen; Mengyan Hu; Xiaoyu Guo; Jie Zheng; Xia Li; Yunqiu Yu
Journal:  Lipids Health Dis       Date:  2021-02-18       Impact factor: 3.876

5.  The endoribonuclease N4BP1 prevents psoriasis by controlling both keratinocytes proliferation and neutrophil infiltration.

Authors:  Chenliang Gou; Wenkai Ni; Panpan Ma; Fengbo Zhao; Zhou Wang; Rong Sun; Yingcheng Wu; Yuanyuan Wu; Miaomiao Chen; Hao Chen; Jie Zhang; Yu Shen; Mingbing Xiao; Cuihua Lu; Renfang Mao; Yihui Fan
Journal:  Cell Death Dis       Date:  2021-05-14       Impact factor: 8.469

6.  Topical Delivery of Rapamycin by Means of Microenvironment-Sensitive Core-Multi-Shell Nanocarriers: Assessment of Anti-Inflammatory Activity in an ex vivo Skin/T Cell Co-Culture Model.

Authors:  Fiorenza Rancan; Xiao Guo; Keerthana Rajes; Polytimi Sidiropoulou; Fatemeh Zabihi; Luisa Hoffmann; Sabrina Hadam; Ulrike Blume-Peytavi; Eckart Rühl; Rainer Haag; Annika Vogt
Journal:  Int J Nanomedicine       Date:  2021-10-22

7.  Abnormal lipid metabolism in epidermal Langerhans cells mediates psoriasis-like dermatitis.

Authors:  Xilin Zhang; Xiaorui Li; Yuanyuan Wang; Youdong Chen; Yijun Hu; Chunyuan Guo; Zengyang Yu; Peng Xu; Yangfeng Ding; Qing-Sheng Mi; Jianhua Wu; Jun Gu; Yuling Shi
Journal:  JCI Insight       Date:  2022-07-08

8.  IFN-κ Is a Rheostat for Development of Psoriasiform Inflammation.

Authors:  Mehrnaz Gharaee-Kermani; Shannon N Estadt; Lam C Tsoi; Sonya J Wolf-Fortune; Jianhua Liu; Xianying Xing; Jonathon Theros; Tamra J Reed; Lori Lowe; Dennis Gruszka; Nicole L Ward; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Invest Dermatol       Date:  2021-08-05       Impact factor: 8.551

9.  Large-Scale Imputation of KIR Copy Number and HLA Alleles in North American and European Psoriasis Case-Control Cohorts Reveals Association of Inhibitory KIR2DL2 With Psoriasis.

Authors:  Richard Ahn; Damjan Vukcevic; Allan Motyer; Joanne Nititham; David McG Squire; Jill A Hollenbach; Paul J Norman; Eva Ellinghaus; Rajan P Nair; Lam C Tsoi; Jorge Oksenberg; John Foerster; Wolfgang Lieb; Stephan Weidinger; Andre Franke; James T Elder; Eric Jorgenson; Stephen Leslie; Wilson Liao
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 8.786

10.  Chromatin accessibility and transcriptome integrative analysis revealed AP-1-mediated genes potentially modulate histopathology features in psoriasis.

Authors:  Xiaoqing Xu; Xianfa Tang; Yuxi Zhang; Zhaobing Pan; Qingping Wang; Lili Tang; Caihong Zhu; Hui Cheng; Fusheng Zhou
Journal:  Clin Epigenetics       Date:  2022-03-11       Impact factor: 6.551
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.